Breast Cancer Biomarkers in Nipple Aspirates from Women Treated With Estrogen Receptor Blockers

Abstract

The purpose of our study is to determine if I)success in collecting nipple aspirate fluid (NAF) increases with experience, 2) NAF biomarkers (cytology, ploidy, cell cycle parameters, and prostate-specific antigen, PSA) change in response to treatment with tamoxifen (TAM) or raloxifene (RAL), and 3) NAP biomarker changes are associated with future breast cancer risk. Our hypothesis is that NAP biomarkers will respond to treatment with TAM or RAL, and that biomarker change(s) will predate clinical findings observed on mammography or physical examination. Postmenopausal women at increased breast cancer risk who have entered the Study of Tamoxifen and Raloxifene (STAR) trial are eligible. Our study collects NAP prior to starting and 6 months after initiating TAM or RAL, as called for by the STAR trial. This multiinstitutional trial currently involves three centers (Thomas Jefferson University, UCLA and Fox Chase Cancer Center).

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Jul 01, 2002
Accession Number
ADA407290

Entities

People

  • Edward R. Sauter

Organizations

  • Thomas Jefferson University

Tags

DTIC Thesaurus Topics

  • Alkenes
  • Biological Markers
  • Biomedical Research
  • Body Fluids
  • Breast Cancer
  • Cell Physiological Processes
  • Data Management
  • Department Of Defense
  • Estrogens
  • Health Care
  • Health Services
  • Mammography
  • Medical Personnel
  • Neoplasms
  • Physical Examination (Medicine)
  • Universities

Fields of Study

  • Medicine

Readers

  • Breast cancer cell signaling and growth regulation.
  • Oncology and Biomarker-Based Cancer Detection.